Company profile for Sol-Gel Technologies

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Our branded ...
We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Our branded product candidates are TWIN and Epsolay (formerly VERED).TWIN is a novel, once-daily, non-antibiotic topical cream containing a fixed-dose combination of encapsulated tretinoin.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
Golda Meir 7, Ness Ziona
Telephone
Telephone
+972-8-9313433
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/20/3191799/0/en/Sol-Gel-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Updates.html

GLOBENEWSWIRE
20 Nov 2025

https://www.globenewswire.com/news-release/2025/09/04/3144352/0/en/Sol-Gel-Announces-Health-Canada-Approval-of-EPSOLAY.html

GLOBENEWSWIRE
04 Sep 2025

https://www.globenewswire.com/news-release/2025/08/15/3134160/0/en/Sol-Gel-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Updates.html

GLOBENEWSWIRE
15 Aug 2025

https://www.globenewswire.com/news-release/2025/05/23/3087406/0/en/Sol-Gel-Reports-First-Quarter-2025-Results.html

GLOBENEWSWIRE
23 May 2025
Sol-Gel Announces Reverse Share Split
Sol-Gel Announces Reverse Share Split

01 May 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/05/01/3072223/0/en/Sol-Gel-Announces-Reverse-Share-Split.html

GLOBENEWSWIRE
01 May 2025

https://www.globenewswire.com/news-release/2025/04/17/3063410/0/en/Sol-Gel-and-Mayne-Pharma-Announce-the-Purchase-of-EPSOLAY-and-TWYNEO-in-the-U-S.html

GLOBENEWSWIRE
17 Apr 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty